摘要
背景:在发达国家,治疗和护理痴呆患者的经济负担问题至关重要。欧盟和其他发达国家正在努力改善人口老龄化的进程,从而导致成本上升。它们的统一登记也是发达国家防治痴呆症战略计划的目标之一。到目前为止,这些计划的个别步骤主要是针对疾病的早期诊断,相关数据的记录到目前为止都处于背景中。目的:本文件的目的是规定一套应在国家一级不断监测的老年痴呆症费用。方法:以阿尔茨海默病为研究对象,对阿尔茨海默病进行文献综述。搜索的关键词是“阿尔茨海默病”和“2010年以后发生的费用”。这些研究将具体说明所监测的费用并确定其最低普及率,从而构成在国家一级为被监测的费用组提出建议的基础。结果:分析结果显示,监测的主要费用类别如下:医疗直接费用(住院治疗、门诊治疗、药物治疗)、非医疗直接费用(日托中心、社区卫生服务、临时护理、病人住宿费用)和间接费用(护理人员专用于病人的时间)。不同名称和费用组的问题要求在这一领域制定共同战略,并确定应监测的最低项目。
关键词: 成本分类,痴呆症,老年痴呆症,直接成本,间接成本,衰老。
Current Alzheimer Research
Title:Missing Uniform Costs Classification for Alzheimer’s Disease Treatment and Care
Volume: 15 Issue: 14
关键词: 成本分类,痴呆症,老年痴呆症,直接成本,间接成本,衰老。
摘要: Background: The importance of the issue of the economic burden of treatment and care for people with dementia is crucial in the developed countries. The European Union and other developed countries are trying to improve the course of aging population which leads to rising costs. Their uniform registration is also one of the objectives of the developed countries’ strategic plans to fight dementia. The individual steps of the plans in practical terms so far are mainly directed to the early diagnosis of diseases, records of the associated data are so far in the background.
Aim: The aim of this paper is to specify a set of costs that should be constantly monitored at the national level within dementia.
Methods: The main method is a literature review focused on Alzheimer's disease. The searched keywords were "Alzheimer's disease" and "costs" incurred after 2010. The studies will specify the monitored costs and determine their minimal penetration, which will then form the basis for recommendations for the monitored group of costs on a national level.
Results: Results of the analysis indicate that the following main cost groups are monitored: medical direct costs (inpatient care, outpatient treatment, medication), non-medical direct costs (day care centres, community health services, respite care, accommodation costs for patients) and indirect costs (time that the carers dedicate to the patient). The issue of different naming and groups of costs calls for a common strategy in this area and defining the minimum items that should be monitored.
Export Options
About this article
Cite this article as:
Missing Uniform Costs Classification for Alzheimer’s Disease Treatment and Care, Current Alzheimer Research 2018; 15 (14) . https://dx.doi.org/10.2174/1567205015666180831103018
DOI https://dx.doi.org/10.2174/1567205015666180831103018 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Therapeutic Development of Interrelated Metabolic and Neurodegenerative Disorders
Current Pharmaceutical Design Dementia After Age 75: Survival in Different Severity Stages and Years of Life Lost
Current Alzheimer Research Substance P and Alzheimer’s Disease: Emerging Novel Roles
Current Alzheimer Research Oxidative Stress in the Pathogenesis of Alzheimer’s Disease and Cerebrovascular Disease with Therapeutic Implications
CNS & Neurological Disorders - Drug Targets Inflammatory and Cell Death Pathways in Brain and Peripheral Blood in Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Reactive Astrogliosis: Role in Alzheimer's Disease
CNS & Neurological Disorders - Drug Targets Angiotensin Receptor Blockers in Hypertension and Cardiovascular Diseases
Cardiovascular & Hematological Agents in Medicinal Chemistry Pyrrolo[2,3-d]Pyrimidines as Kinase Inhibitors
Current Medicinal Chemistry Xuesaitong May Protect Against Ischemic Stroke by Modulating Microglial Phenotypes and Inhibiting Neuronal Cell Apoptosis via the STAT3 Signaling Pathway
CNS & Neurological Disorders - Drug Targets Preface [Hot topic: Protein Misfolding in the Amyloidoses and other Disorders (Guest Editor: David R. Howlett)]
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents The Hypothesis of the Catalytic Action of Nucleic Acid on the Conversion of Prion Protein
Protein & Peptide Letters Pharmacotherapy for Obesity
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Association of PICALM Gene Polymorphisms with Alzheimer's Disease: Evidence from an Updated Meta-Analysis
Current Alzheimer Research Neurodegeneration in Amygdala Precedes Hippocampus in the APPswe/ PS1dE9 Mouse Model of Alzheimer’s Disease
Current Alzheimer Research Nano-biotechnology and its Innovative Perspective in Diabetes Management
Mini-Reviews in Medicinal Chemistry Tuberculosis Infections of the Central Nervous System
Central Nervous System Agents in Medicinal Chemistry Commentary (Research Highlights: Targeted Inhibition of miR-155 Promotes Post-Stroke Neovascularization and Functional Recovery)
CNS & Neurological Disorders - Drug Targets Late Onset Alzheimer’s Disease: Novel Clinical Prospects for the Future
Current Neurovascular Research Heparin - a Key Drug in the Treatment of the Circulatory Degenerative Diseases: Controlling its Action with Polymers
Current Pharmaceutical Design The Complex Inter-Relationship Between Diabetes and Schizophrenia
Current Diabetes Reviews